肿瘤相关性肾病 中国就医指南

Tumor-associated nephropathy (TAN) is a heterogeneous group of kidney disorders directly linked to the presence, progression, or treatment of malignancy. It is not a single disease but rather an umbrella term encompassing paraneoplastic glomerulopathies (e.g., membranous nephropathy, minimal change disease, IgA nephropathy), tumor infiltration of renal parenchyma, obstructive uropathy due to retroperitoneal lymphadenopathy or direct compression, chemotherapy- or immunotherapy-induced nephrotoxicity (e.g., cisplatin, ifosfamide, checkpoint inhibitors), and hematologic malignancy–related complications such as light-chain cast nephropathy in multiple myeloma or tumor lysis syndrome. Pathogenesis varies by subtype: immune-mediated mechanisms dominate paraneoplastic forms—often involving cross-reactive autoantibodies triggered by tumor antigens (e.g., anti-PLA2R in tumor-associated membranous nephropathy); direct infiltration reflects metastatic spread; obstruction arises from mechanical compromise of urinary outflow; and metabolic insults stem from rapid cell turnover or drug-induced tubular injury. Epidemiologically, TAN accounts for approximately 1–3% of all secondary glomerular diseases in adult nephrology practice, with higher prevalence among patients aged ≥60 years and those with solid tumors (lung, gastric, colorectal, prostate) or hematologic cancers (lymphoma, myeloma). Risk factors include advanced cancer stage, elevated tumor burden, specific oncologic therapies (especially platinum-based regimens and PD-1/PD-L1 inhibitors), preexisting chronic kidney disease (CKD), hypertension, diabetes, and genetic susceptibility to immune dysregulation. Clinically, TAN manifests variably: nephrotic-range proteinuria, microscopic hematuria, acute or subacute kidney injury, hypertension, edema, and—in severe cases—rapidly progressive glomerulonephritis or end-stage renal disease. Quality of life is significantly impaired: patients experience fatigue, fluid retention, recurrent infections, treatment-related anxiety, reduced physical functioning, and psychosocial distress stemming from dual disease burden—cancer and kidney failure. Early recognition is critical, as timely oncologic intervention (e.g., tumor resection or targeted therapy) may reverse renal injury in paraneoplastic or obstructive cases, whereas delayed diagnosis often leads to irreversible fibrosis and accelerated CKD progression. Multidisciplinary management involving nephrologists, oncologists, and pathologists—including kidney biopsy when safe and indicated—is essential for accurate classification and personalized therapeutic strategy.

# 肿瘤相关性肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：早期肾损伤（eGFR ≥60 mL/min/1.73m²）、无活动性肿瘤进展、蛋白尿＜3.5 g/d者。

• •基础治疗：控制原发肿瘤（联合肿瘤科）、ACEI/ARB降尿蛋白（如缬沙坦，月均药费 200–600元）
• •免疫调节：糖皮质激素±环磷酰胺（需监测骨髓/肝肾功能），月均药费 800–2500元；利妥昔单抗（按体重给药，单次 8000–15000元）
• •检查费：24h尿蛋白定量+血清白蛋白+eGFR+肿瘤标志物（含CT/MRI定位）1200–3500元/次

二、介入/核心治疗方案

适用人群：继发膜性肾病伴高凝/血栓风险、或需快速控制肾病综合征者。

• •肾动脉灌注化疗（限实体瘤转移致肾血管受累）：含术前DSA+灌注，28000–45000元/次（含术前检查 3200–5800元）
• •血浆置换（顽固性冷球蛋白血症相关肾炎）：单次 2200–3600元，疗程5–10次

三、特殊复杂方案

晚期/耐药/并发症：多发性骨髓瘤相关肾损害（管型肾病）、淋巴瘤浸润性肾病。

• •硼替佐米+地塞米松方案：周期治疗（3个月），总药费 65000–120000元；透析过渡支持（血透/腹透）月均 3000–8000元

四、方案快速选择指南

• •预算≤2万元/年：首选ACEI/ARB+定期随访（适合轻度蛋白尿）
• •预算3–8万元/年：加用利妥昔单抗或小剂量环磷酰胺（中重度肾病综合征）
• •急重症/晚期合并多器官受累：转入肿瘤-肾病联合诊疗单元，启动靶向+支持治疗（年均支出≥10万元）